These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

163 related items for PubMed ID: 15577039

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Possible involvement of circulating fibroblast growth factor 23 in the development of secondary hyperparathyroidism associated with renal insufficiency.
    Shigematsu T, Kazama JJ, Yamashita T, Fukumoto S, Hosoya T, Gejyo F, Fukagawa M.
    Am J Kidney Dis; 2004 Aug; 44(2):250-6. PubMed ID: 15264182
    [Abstract] [Full Text] [Related]

  • 5. [Clinical aspect of recent progress in phosphate metabolism. Pathophysiology of secondary hyperparathyroidism in chronic kidney disease].
    Goto S, Fukagawa M.
    Clin Calcium; 2009 Jun; 19(6):809-14. PubMed ID: 19483275
    [Abstract] [Full Text] [Related]

  • 6. Parathyroid function in chronic kidney disease: role of FGF23-Klotho axis.
    Koizumi M, Komaba H, Fukagawa M.
    Contrib Nephrol; 2013 Jun; 180():110-23. PubMed ID: 23652554
    [Abstract] [Full Text] [Related]

  • 7. The impact of diabetes mellitus on vitamin D metabolism in predialysis patients.
    Tanaka H, Hamano T, Fujii N, Tomida K, Matsui I, Mikami S, Nagasawa Y, Ito T, Moriyama T, Horio M, Imai E, Isaka Y, Rakugi H.
    Bone; 2009 Nov; 45(5):949-55. PubMed ID: 19631779
    [Abstract] [Full Text] [Related]

  • 8. FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis.
    Shimada T, Hasegawa H, Yamazaki Y, Muto T, Hino R, Takeuchi Y, Fujita T, Nakahara K, Fukumoto S, Yamashita T.
    J Bone Miner Res; 2004 Mar; 19(3):429-35. PubMed ID: 15040831
    [Abstract] [Full Text] [Related]

  • 9. Fibroblast growth factor-23 helps explain the biphasic cardiovascular effects of vitamin D in chronic kidney disease.
    Hu P, Xuan Q, Hu B, Lu L, Wang J, Qin YH.
    Int J Biol Sci; 2012 Mar; 8(5):663-71. PubMed ID: 22606047
    [Abstract] [Full Text] [Related]

  • 10. Postprandial mineral metabolism and secondary hyperparathyroidism in early CKD.
    Isakova T, Gutierrez O, Shah A, Castaldo L, Holmes J, Lee H, Wolf M.
    J Am Soc Nephrol; 2008 Mar; 19(3):615-23. PubMed ID: 18216315
    [Abstract] [Full Text] [Related]

  • 11. Fibroblast growth factor-23 in early chronic kidney disease: additional support in favor of a phosphate-centric paradigm for the pathogenesis of secondary hyperparathyroidism.
    Evenepoel P, Meijers B, Viaene L, Bammens B, Claes K, Kuypers D, Vanderschueren D, Vanrenterghem Y.
    Clin J Am Soc Nephrol; 2010 Jul; 5(7):1268-76. PubMed ID: 20448073
    [Abstract] [Full Text] [Related]

  • 12. Relationship between plasma fibroblast growth factor-23 concentration and bone mineralization in children with renal failure on peritoneal dialysis.
    Wesseling-Perry K, Pereira RC, Wang H, Elashoff RM, Sahney S, Gales B, Jüppner H, Salusky IB.
    J Clin Endocrinol Metab; 2009 Feb; 94(2):511-7. PubMed ID: 19050056
    [Abstract] [Full Text] [Related]

  • 13. Total parathyroidectomy reduces elevated circulating fibroblast growth factor 23 in advanced secondary hyperparathyroidism.
    Sato T, Tominaga Y, Ueki T, Goto N, Matsuoka S, Katayama A, Haba T, Uchida K, Nakanishi S, Kazama JJ, Gejyo F, Yamashita T, Fukagawa M.
    Am J Kidney Dis; 2004 Sep; 44(3):481-7. PubMed ID: 15332221
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Interaction between serum FGF-23 and PTH in renal phosphate excretion, a case-control study in hypoparathyroid patients.
    Saki F, Kassaee SR, Salehifar A, Omrani GHR.
    BMC Nephrol; 2020 May 12; 21(1):176. PubMed ID: 32398014
    [Abstract] [Full Text] [Related]

  • 17. FGF-23 in patients with end-stage renal disease on hemodialysis.
    Imanishi Y, Inaba M, Nakatsuka K, Nagasue K, Okuno S, Yoshihara A, Miura M, Miyauchi A, Kobayashi K, Miki T, Shoji T, Ishimura E, Nishizawa Y.
    Kidney Int; 2004 May 12; 65(5):1943-6. PubMed ID: 15086938
    [Abstract] [Full Text] [Related]

  • 18. Fibroblast growth factor (FGF)-23 in patients with primary hyperparathyroidism.
    Yamashita H, Yamashita T, Miyamoto M, Shigematsu T, Kazama JJ, Shimada T, Yamazaki Y, Fukumoto S, Fukagaw M, Noguchi S.
    Eur J Endocrinol; 2004 Jul 12; 151(1):55-60. PubMed ID: 15248822
    [Abstract] [Full Text] [Related]

  • 19. Direct evidence for a causative role of FGF23 in the abnormal renal phosphate handling and vitamin D metabolism in rats with early-stage chronic kidney disease.
    Hasegawa H, Nagano N, Urakawa I, Yamazaki Y, Iijima K, Fujita T, Yamashita T, Fukumoto S, Shimada T.
    Kidney Int; 2010 Nov 12; 78(10):975-80. PubMed ID: 20844473
    [Abstract] [Full Text] [Related]

  • 20. Clinical relevance of FGF-23 in chronic kidney disease.
    Seiler S, Heine GH, Fliser D.
    Kidney Int Suppl; 2009 Dec 12; (114):S34-42. PubMed ID: 19946326
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.